EIB or not EIB? That is the question.
This editorial comments on the paper of Pedersen et al. focusing, in particular, on the criteria set by the IOC-MC for documenting exercise-induced asthma and exercise-induced bronchoconstriction (and therefore permitting the use of beta-2 adrenergic drugs) in athletes participating in the Beijing Olympic Games.